The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.